The first quarter of 2026 has highlighted a strong resurgence of investor confidence in cell therapy startups, with multiple companies securing significant Series A funding to advance next-generation treatments. These startups are not only pushing the boundaries of oncology-focused CAR-T

The rapid evolution of CRISPR gene-editing technologies is transforming how inherited diseases are treated, shifting the focus from symptom management to potential one-time, curative therapies. In 2026, a new wave of biotech innovators is leading this revolution, leveraging precision editing